In extended trading, Rigel Pharmaceuticals’ shares rose 14% after the company announced that the U.S. health regulator had authorised its medicine for the therapy of individuals with a specific kind of leukemia The medication, which will be marketed under the name Rezlidhia, has been given the green light by the Food and Drug Administration for the treatment of acute myeloid leukaemia in people who have a genetic mutation that makes them more vulnerable to the disease.
Related: Provention Bio’s one-of-its-kind diabetes medication snags FDA’s nod
Following Tavalisse, a drug for treating immune thrombocytopenic purpura, a rare bleeding illness, Rezlidhia will be the firm’s second medication to get FD’s clearance.
Read More from Reuters
